Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2014; 20(46): 17368-17375
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17368
Published online Dec 14, 2014. doi: 10.3748/wjg.v20.i46.17368
Hematopoietic stem cell transplantation for non-malignant gastrointestinal diseases
Abdulbaqi Al-toma, Department of Internal Medicine and Gastroenterology, 3430 EM Nieuwegein, The Netherlands
Petula Nijeboer, Gerd Bouma, Chris JJ Mulder, Department of Gastroenterology, VU University Medical Centre, 1005 MB Amsterdam, The Netherlands
Otto Visser, Department of Hematology, VU University Medical Centre, 1005 MB Amsterdam, The Netherlands
Author contributions: Al-toma A and Nijeboer P have performed literature search and wrote the manuscript; Bouma G, Visser O and Mulder CJJ have critically revised the manuscript, provided scientific input and feedback.
Correspondence to: Abdulbaqi Al-toma, MD, PhD, Gastroenterologist, Department of internal medicine and gastroenterology, St. Antonius hospital, Koekoeslaan 1, 3430 EM Nieuwegein, The Netherlands. a.altoma@antoniusziekenhuis.nl
Telephone: +31-30-6099111 Fax: +31-30-6056357
Received: March 7, 2014
Revised: April 30, 2014
Accepted: September 29, 2014
Published online: December 14, 2014
Revised: April 30, 2014
Accepted: September 29, 2014
Published online: December 14, 2014
Core Tip
Core tip: Hematopoietic stem cell transplantation (HSCT) can be used to treat malignant and non-malignant diseases. This therapeutic modality is based on using immunoablation followed by reinfusion of hematopoietic progenitor cells to regenerate naive T-lymphocytes. HSCT and mesenchymal SCT have been proved successful in treating refractory inflammatory conditions such as Crohn’s disease and refractory celiac disease type II. The ultimate target of aggressively treating this type of celiac disease is to prevent development of lymphoma. Data in end-stage liver diseases are also encouraging.